collagenase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5051	9001-12-1

Description:

Molecule	Description
Synonyms: collagenase xiaflex collagenase clostridium histolyticum	purified collagenase clostridium histolyticum, consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

collagenase
xiaflex
collagenase clostridium histolyticum

purified collagenase clostridium histolyticum, consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.90	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 4, 1965	FDA	ADVANCE BIOFACTURES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contusion	408.62	30.55	149	1455	149895	63337523
Skin hyperpigmentation	184.20	30.55	40	1564	5881	63481537
Haemosiderin stain	172.65	30.55	18	1586	0	63487418
Skin indentation	136.22	30.55	16	1588	31	63487387
Skin discolouration	122.19	30.55	43	1561	37785	63449633
Lipodystrophy acquired	118.91	30.55	22	1582	1430	63485988
Skin laxity	104.49	30.55	12	1592	17	63487401
Tendon rupture	76.24	30.55	21	1583	8218	63479200
Nodule	60.60	30.55	22	1582	21004	63466414
Blood blister	48.54	30.55	11	1593	1947	63485471
Wound complication	41.44	30.55	11	1593	3736	63483682
Off label use	38.44	30.55	64	1540	674398	62813020
Axillary pain	37.79	30.55	9	1595	1974	63485444
Skin laceration	31.36	30.55	14	1590	22694	63464724

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fracture of penis	1090.79	45.54	140	3097	95	34953599
Penile swelling	791.40	45.54	124	3113	726	34952968
Penile contusion	678.94	45.54	90	3147	102	34953592
Penile haematoma	643.69	45.54	88	3149	148	34953546
Corpora cavernosa surgery	552.72	45.54	69	3168	23	34953671
Penile pain	439.03	45.54	82	3155	1481	34952213
Drug ineffective	306.52	45.54	283	2954	456468	34497226
Contusion	261.17	45.54	105	3132	36259	34917435
Skin laceration	252.44	45.54	78	3159	12431	34941263
Penis disorder	153.23	45.54	33	3204	1240	34952454
Swelling	151.01	45.54	75	3162	42291	34911403
Injection site pain	147.80	45.54	72	3165	38933	34914761
Penile haemorrhage	144.30	45.54	28	3209	619	34953075
Injection site swelling	143.78	45.54	50	3187	11477	34942217
Genital contusion	132.64	45.54	16	3221	0	34953694
Penile blister	113.18	45.54	17	3220	70	34953624
Blood blister	112.83	45.54	27	3210	1632	34952062
Inappropriate schedule of product administration	106.13	45.54	68	3169	62228	34891466
Injection site bruising	105.76	45.54	37	3200	8626	34945068
Skin graft	76.35	45.54	16	3221	525	34953169
Painful erection	75.44	45.54	14	3223	241	34953453
Injection site haematoma	66.64	45.54	18	3219	1767	34951927
Ecchymosis	56.87	45.54	22	3215	6781	34946913
Penile size reduced	53.20	45.54	10	3227	185	34953509
Wrong technique in product usage process	50.80	45.54	35	3202	35951	34917743

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Penile swelling	729.79	33.21	101	3188	565	79740534
Fracture of penis	671.24	33.21	80	3209	84	79741015
Penile haematoma	564.14	33.21	69	3220	106	79740993
Penile contusion	486.89	33.21	58	3231	60	79741039
Penile pain	391.50	33.21	62	3227	949	79740150
Corpora cavernosa surgery	363.96	33.21	42	3247	23	79741076
Contusion	269.27	33.21	128	3161	148648	79592451
Skin laceration	192.59	33.21	64	3225	28898	79712201
Penis disorder	130.51	33.21	24	3265	912	79740187
Penile haemorrhage	129.92	33.21	22	3267	515	79740584
Blood blister	112.78	33.21	26	3263	3031	79738068
Genital contusion	100.08	33.21	11	3278	0	79741099
Injection site pain	98.17	33.21	63	3226	129775	79611324
Drug ineffective	91.12	33.21	160	3129	1080753	78660346
Inappropriate schedule of product administration	89.22	33.21	60	3229	133568	79607531
Tendon rupture	77.33	33.21	26	3263	12100	79728999
Penile blister	70.96	33.21	10	3279	64	79741035
Injection site swelling	68.28	33.21	35	3254	47097	79694002
Axillary pain	67.26	33.21	16	3273	2133	79738966
Injection site bruising	63.92	33.21	32	3257	40970	79700129
Skin graft	61.51	33.21	13	3276	1014	79740085
Skin discolouration	60.97	33.21	31	3258	41003	79700096
Injection site haematoma	58.85	33.21	17	3272	4810	79736289
Ecchymosis	56.96	33.21	22	3267	15184	79725915
Painful erection	55.28	33.21	9	3280	164	79740935
Haemosiderin stain	54.58	33.21	6	3283	0	79741099
Swelling	52.38	33.21	54	3235	216657	79524442
Pain in extremity	44.11	33.21	64	3225	364474	79376625
Wound complication	41.12	33.21	13	3276	4980	79736119
Oedema peripheral	40.72	33.21	51	3238	252237	79488862
Penile oedema	36.96	33.21	7	3282	312	79740787
Skin indentation	36.70	33.21	5	3284	24	79741075

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D03BA02	DERMATOLOGICALS PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS ENZYMES Proteolytic enzymes
ATC	D03BA52	DERMATOLOGICALS PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS ENZYMES Proteolytic enzymes
ATC	M09AB02	MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Enzymes
FDA Chemical/Ingredient	N0000006395	Collagenases
FDA EPC	N0000175843	Collagen-specific Enzyme

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Induratio penis plastica	indication	1335005	DOID:8616
Dupuytren's disease of finger, with contracture	indication	203051006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D09596	KEGG_DRUG
4018477	VUID
N0000146799	NUI
4018477	VANDF
4029767	VANDF
C0162745	UMLSCUI
CHEMBL2108709	ChEMBL_ID
75007581	PUBCHEM_CID
DB00048	DRUGBANK_ID
58939	RXNORM
170479	MMSL
26980	MMSL
4497	MMSL
72861	MMSL
d07548	MMSL
001890	NDDF
417416003	SNOMEDCT_US
56355009	SNOMEDCT_US
772213007	SNOMEDCT_US
786084006	SNOMEDCT_US
9X7O8V25IT	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
COLLAGENASE SANTYL	HUMAN PRESCRIPTION DRUG LABEL	1	50484-010	OINTMENT	250 [arbU]	TOPICAL	BLA	10 sections
Kimchi Vitaminchewable multivitamin	HUMAN OTC DRUG LABEL	11	52102-1001	TABLET, CHEWABLE	5.63 mg	ORAL	unapproved drug other	4 sections
Qwo	HUMAN PRESCRIPTION DRUG LABEL	1	73611-300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	0.23 mg	INTRALESIONAL	BLA	27 sections
Qwo	HUMAN PRESCRIPTION DRUG LABEL	1	73611-300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	0.23 mg	INTRALESIONAL	BLA	27 sections
Qwo	HUMAN PRESCRIPTION DRUG LABEL	1	73611-300	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	0.23 mg	INTRALESIONAL	BLA	27 sections